The SOGC's recent statement regarding Menopausal Hormone Therapy (MHT) as it relates to this week’s decision by the U.S. Food and Drug Administration (FDA) to remove ‘black-box’ warnings was featured in a Globe and Mail story this week. The article stressed that the SOGC hopes the announcement will encourage women to explore MHT options with their physician and highlights the SOGC’s guidance on the safety of hormone therapy in the treatment of menopausal symptoms.
Read the full story here: https://www.theglobeandmail.com/canada/article-menopause-treatment-us-fda-hormone-therapy-warnings-removal/
For more information, please refer to the SOGC’s clinical practice guideline on menopause: https://sogc.org/common/Uploaded%20files/ACSC/ACSC2025/gui422aCPG2110E.pdf